Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
A new drug for rare heart amyloidosis shows promise in a specific patient subgroup, cutting death risk by over half when the right patients are selected.
The CARES Phase 3 trial of anselamimab in newly diagnosed advanced AL amyloidosis did not meet its primary composite endpoint in the overall population of 406 patients. However, a clinically meaningful and nominally statistically significant benefit was observed in the kappa isotype subgroup (n=72), with 62% reduction in all-cause mortality and 71% reduction in cardiovascular hospitalizations, suggesting isotype-stratified patient selection may be key for future development.
What the study was
- Study design
- Randomized controlled trial (Phase 3, double-blind, placebo-controlled)
- Population
- Newly diagnosed AL amyloidosis (European Mayo stage IIIa or IIIb); international multicenter
- Sample size
- 406
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of clinical oncology
Why it surfaced
Phase 3 RCT in high-unmet-need rare disease (stage IIIa/IIIb AL amyloidosis has poor prognosis). Antifibril antibody mechanism is novel. Kappa subgroup benefit is clinically meaningful (62% ACM reduction) though primary endpoint missed overall. JCO publication adds credibility. Important signal for biomarker-stratified rare disease trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.